Appendix 6. Report of negative events.

Study ID (author / year / reference)	Deterioration	Adverse events	Severe adverse events	Novel Symptoms	Dropout	Nonresponse	Unwanted events
Agyapong (2017) [35]							
Andersson (2013) [36]							
Arjadi (2018) [37]							
Berger (2011) [38]							
Berger (2018) [39]							
Blackwell (2015) [40]							
Bowers (1993) [41]							
Carlbring (2013) [42]							
Celano (2017) [43]							
Choi (2012) [44]							
Choi (2014) [45]							
Corruble (2016) [46]							
Egede (2015) [47]							
Forand (2018) [48]							
Forsell (2017) [49]							
Gilbody (2016) [50]							
Graaf (2009) [51]							
Holländare (2011) [16]							
Hunkeler (2012) [52]							
Johansson (2012) [53]							
Johansson (2012) [54]							
Johansson (2013) [55]							
Kenter (2016) [32]							
Kessler (2009) [56]							
Kivi (2014) [57]							
Kok (2015) [29]							
Hirsch (2018) [58]							

Lam (2013) [59]				
Lang (2012) [60]				
Lappalainen (2015) [61]				
Lindner (2014) [62]				
Löbner (2018) [63]				
Luxton (2016) [64]				
Ly (2014) [65]				
Ly (2015) [66]				
Mantani (2017) [67]				
Meyer (2015) [68]				
Milgrom (2016) [69]				
Mohr (2011) [70]				
Mohr (2012) [71]				
Mohr (2013) [72]				
Montero-Marin (2016) [73]				
Nakao (2018) [74]				
Nyström (2017) [75]				
O'Mahen (2014) [76]				
Perini (2009) [17]				
Reins (2019) [77]				
Ren (2016) [78]				
Richards (2013) [79]				
Rollman (2018) [80]				
Rosso (2017) [81]				
Sandoval (2017) [82]				
Schlicker (2018) [30]				
Schuver (2016) [83]				
Selmi (1990) [84]				
Smith (2017) [85]				
Steinmann (2020) [15]				
Thase (2018) [86]				
Titov (2010) [87]				

Titov (2011) [88]							
Torkan (2014) [89]							
Vernmark (2010) [90]							
Watkins (2012) [91]							
Watts (2013) [92]							
Williams (2013) [93]							
Williams (2015) [94]							
Wright (2005) [95]							
Zagorscak (2018) [96]							
Zwerenz (2017) [97]							
Zwerenz (2017) [31]							
13 further published trials we	ere identified in the co	urse of the search up	odate (August 2020) ir	the Cochrane Centra	al Register of Controll	ed Trials. Publications	are listed below
Dennis (2020) [98]							
Flygare (2020) [99]							
Gili (2020) [100]							
Hur (2018) [101]							
Jannati (2020) [102]							
Johansson (2019) [108]							
Kooistra (2019) [103]							
Mohr (2019) [33]							
Oehler (2020) [104]							
Pfeiffer (2020) [105]							
Pihlaja (2020) [106]							
Richards (2020) [34]							
Welch (2019) [107]							

Note. Color highlighting of cells indicates whether or not information concerning different categories of negative events were reported in included studies: green = report concerning information on specific category of negative events (see first line); red = no report concerning information on specific category of negative events (see first line); yellow (only applied for dropouts) = report of other kind of dropouts (eg, withdrawals from study, treatment completers as defined by authors) that did not capture dropouts from treatment (ie, inverse of the completion rate, etc.).